Results 151 to 160 of about 33,038 (222)

Androgenic effects of 11-oxyandrogens in castration-resistant prostate cancer. [PDF]

BMC Cancer
Lapointe-Belleau A, Rouleau M, Villeneuve L, Descarreaux J, Caron P, Beaudoin C, Uchil A, Simonyan D, Dahmani C, Joly-Beauparlant C, Gélinas V, Droit A, Marcoux N, Castonguay V, Lacombe L, Lévesque É, Guillemette C.   +16 more
europepmc   +1 more source

Case Report: Niraparib-abiraterone in HRR-mutated metastatic castration-resistant prostate cancer: clinical insights from five cases. [PDF]

Front Oncol
Vascotto IA, Catalano M, Venturini J, Calandrelli C, Mancini S, Pratesi L, Izzi M, Mela MM, Rossi V, Francini E, Pillozzi S, Antonuzzo L, Roviello G.   +12 more
europepmc   +1 more source

HIF1 inhibition targets tumoral and myeloid cells, and is a promising therapy for metastatic castration-resistant prostate cancer. [PDF]

Cell Death Dis
Yanushko D, Pichot A, Vincent A, Keime C, Laverny G, Metzger D.   +5 more
europepmc   +1 more source

Molecular insights into DDX3X-androgen receptor mRNA regulation via non-canonical G-quadruplex in castration-resistant prostate cancer. [PDF]

Oncogene
Zhang H, Liu TT, Wu F, Colah AN, Ricke EA, Li L, Putnam AA, Ricke WA.   +7 more
europepmc   +1 more source

A phase I/II trial of concurrent chemo-hormonal enzalutamide and cabazitaxel in patients with metastatic castration-resistant prostate cancer. [PDF]

Oncologist
Graff JN, Smith CEP, Sokolova AO, Qian DZ, Beer TM, Latour E, Bailey S, Kreitner D, Grivas P, Schweizer MT, Higano CS, Alumkal JJ, Vuky J, Yu EY, Cheng HH.   +14 more
europepmc   +1 more source

Rethinking combination strategies in metastatic castration-resistant prostate cancer (mCRPC)-lessons from KEYNOTE-641. [PDF]

Transl Androl Urol
Nguyen MD, Vinh-Hung V, Verschraegen C, Wang P.   +3 more
europepmc   +1 more source

Two Cases of Metastatic Castration-Resistant Prostate Cancer With Long-Term Survival Treated With Abiraterone. [PDF]

Clin Case Rep
Une M, Yamamoto S, Fuse H, Fujiwara R, Yonese J, Noda K.   +5 more
europepmc   +1 more source